10:43 AM EDT, 08/20/2025 (MT Newswires) -- HLS Therapeutics ( HLTRF ) on Wednesday said it has entered into a new credit agreement for up to C$107 million, highlighting the CAD-denominated facility reduces its FX exposure and lowers its interest rate.

A statement noted the agreement consists of a C$79 million term credit facility, a C$14 million delayed draw facility and a C$14 million revolving credit facility. In addition, HLS can increase facilities further through an uncommitted C$40 million accordion facility (subject to lender agreement).

It said the C$79 million term loan replaces a US$56 million term loan, creating a natural currency hedge against HLS's predominantly Canadian operations.

"We are pleased to finalize this new credit agreement with National Bank and our syndicate partners, which reflects their confidence in our outlook," said John Hanna, chief financial officer. "The agreement delivers improved terms that reflect our strengthened financial position and provides enhanced financial flexibility and cash flow to pursue our capital allocation priorities such as share buybacks and portfolio expansion."

The company's shares are down 1.1% to $5.10, on the Toronto Stock Exchange.

Price: 5.10, Change: -0.06, Percent Change: -1.16